Clinical Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Henson, J. D.
Right arrow Articles by Reddel, R. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Henson, J. D.
Right arrow Articles by Reddel, R. R.
Clinical Cancer Research Vol. 11, 217-225, January 2005
© 2005 American Association for Cancer Research


Imaging, Diagnosis, Prognosis

A Robust Assay for Alternative Lengthening of Telomeres in Tumors Shows the Significance of Alternative Lengthening of Telomeres in Sarcomas and Astrocytomas

Jeremy D. Henson1, Jonathan A. Hannay6, Stanley W. McCarthy2, Janice A. Royds7,8, Thomas R. Yeager1, Robert A. Robinson9, Stephen B. Wharton8, David A. Jellinek8, Susan M. Arbuckle3, Jinyoung Yoo10, Bruce G. Robinson4, Diana L. Learoyd4, Paul D. Stalley2, S. Fiona Bonar5, Dihua Yu6, Raphael E. Pollock6 and Roger R. Reddel1

1 Children's Medical Research Institute; 2 Royal Prince Alfred Hospital; 3 Children's Hospital Westmead; 4 Royal North Shore Hospital, University of Sydney; and 5 Douglass Hanly Moir Pathology, Sydney, New South Wales, Australia; 6 MD Anderson Cancer Center, Houston, Texas; 7 University of Otago, Dunedin, New Zealand; 8 Royal Hallamshire Hospital, Sheffield, United Kingdom; 9 University of Iowa, Iowa City, Iowa; and 10 Department of Pathology, St Vincent's Hospital, Catholic University, Suwon, Kyungkido, South Korea

Requests for reprints: Roger Reddel, Children's Medical Research Institute, 214 Hawkesbury Road, Westmead, New South Wales 2145, Australia. Phone: 61-2-96872800; Fax: 612-968-72120; E-mail:rreddel{at}cmri.usyd.edu.au.

Purpose and Experimental Design: Telomeres of tumor cells may be maintained by telomerase or by alternative lengthening of telomeres (ALT). The standard ALT assay requires Southern analysis of high molecular weight genomic DNA. We aimed to establish and validate an ALT assay suitable for archived paraffin-embedded tumors and to use it to examine the prevalence and clinical significance of ALT in various types of tumors that are often telomerase negative.

Results: To assay for ALT, we detected ALT-associated promyelocytic leukemia (PML) bodies (APBs) by combined PML immunofluorescence and telomere fluorescence in situ hybridization. APBs are PML nuclear domains containing telomeric DNA and are a known hallmark of ALT in cell lines. The APB assay concurred with the standard ALT assay in 62 of 62 tumors and showed that 35% of 101 soft tissue sarcomas (STS), 47% of 58 osteosarcomas (especially younger patients), 34% of 50 astrocytomas, and 0% of 17 papillary thyroid carcinomas were ALT positive (ALT+). The prevalence of ALT varied greatly among different STS subtypes: malignant fibrous histiocytomas, 77%; leiomyosarcomas, 62%; liposarcomas, 33%; synovial sarcomas, 9%; and rhabdomyosarcomas, 6%. ALT correlated with survival in glioblastoma multiforme and occurred more often in lower-grade astrocytomas, but ALT+ and ALT– sarcomas were equally aggressive in terms of grade and clinical outcome.

Conclusion: The APB assay for ALT is suitable for paraffin-embedded tumors. It showed that a substantial proportion of STS, osteosarcomas, and astrocytomas, but not papillary thyroid carcinomas use ALT. APB positivity correlated strongly with survival of patients with astrocytomas.

Key Words: ALT-associated PML body • soft tissue sarcoma • osteosarcoma • glioblastoma multiforme • papillary carcinoma of thyroid




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
R. Villa, M. G. Daidone, R. Motta, L. Venturini, C. De Marco, A. Vannelli, S. Kusamura, D. Baratti, M. Deraco, A. Costa, et al.
Multiple Mechanisms of Telomere Maintenance Exist and Differentially Affect Clinical Outcome in Diffuse Malignant Peritoneal Mesothelioma
Clin. Cancer Res., July 1, 2008; 14(13): 4134 - 4140.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
T. Else, T. J. Giordano, and G. D. Hammer
Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. E. Bernardo, N. Zaffaroni, F. Novara, A. M. Cometa, M. A. Avanzini, A. Moretta, D. Montagna, R. Maccario, R. Villa, M. G. Daidone, et al.
Human Bone Marrow Derived Mesenchymal Stem Cells Do Not Undergo Transformation after Long-term In vitro Culture and Do Not Exhibit Telomere Maintenance Mechanisms
Cancer Res., October 1, 2007; 67(19): 9142 - 9149.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. A. Compton, J.-H. Choi, A. J. Cesare, S. Ozgur, and J. D. Griffith
Xrcc3 and Nbs1 Are Required for the Production of Extrachromosomal Telomeric Circles in Human Alternative Lengthening of Telomere Cells
Cancer Res., February 15, 2007; 67(4): 1513 - 1519.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Costa, M. G. Daidone, L. Daprai, R. Villa, S. Cantu, S. Pilotti, L. Mariani, A. Gronchi, J. D. Henson, R. R. Reddel, et al.
Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression.
Cancer Res., September 1, 2006; 66(17): 8918 - 8924.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
Y.-J. Chen, V. Hakin-Smith, M. Teo, G. E. Xinarianos, D. A. Jellinek, T. Carroll, D. McDowell, M. R. MacFarlane, R. Boet, B. C. Baguley, et al.
Association of Mutant TP53 with Alternative Lengthening of Telomeres and Favorable Prognosis in Glioma.
Cancer Res., July 1, 2006; 66(13): 6473 - 6476.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Muntoni and R. R. Reddel
The first molecular details of ALT in human tumor cells
Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R191 - R196.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. E. Johnson, R. J. Varkonyi, J. Schwalm, R. Cragle, A. Klein-Szanto, A. Patchefsky, E. Cukierman, M. von Mehren, and D. Broccoli
Multiple Mechanisms of Telomere Maintenance Exist in Liposarcomas
Clin. Cancer Res., August 1, 2005; 11(15): 5347 - 5355.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
J. N. Jeyapalan, H. Varley, J. L. Foxon, R. E. Pollock, A. J. Jeffreys, J. D. Henson, R. R. Reddel, and N. J. Royle
Activation of the ALT pathway for telomere maintenance can affect other sequences in the human genome
Hum. Mol. Genet., July 1, 2005; 14(13): 1785 - 1794.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. M. Linardic, D. L. Downie, S. Qualman, R. C. Bentley, and C. M. Counter
Genetic Modeling of Human Rhabdomyosarcoma
Cancer Res., June 1, 2005; 65(11): 4490 - 4495.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.